Eli Lilly Insilico Deal Expands AI Collaboration
Eli Lilly Insilico deal gives Lilly exclusive preclinical rights, $115M upfront and up to $2.8B in milestones, likely repricing AI-discovery peers.
KEY TAKEAWAYS
- Deal grants Lilly exclusive worldwide rights to select preclinical oral therapeutics.
- Insilico received $115 million upfront plus up to $2.8 billion in milestones and tiered royalties.
- Joint R&D pairs Insilico's Pharma.AI discovery models with Lilly's clinical development capabilities.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Eli Lilly (LLY) expanded its collaboration with Insilico Medicine on March 29, 2026, granting Lilly exclusive worldwide rights to selected preclinical oral therapeutics and launching joint research and development using Insilico’s AI discovery platform.
Deal Terms and Strategic Context
The agreement includes an upfront payment of $115 million to Insilico, potential development, regulatory, and commercial milestones totaling about $2.75 billion, and tiered royalties on net sales. Lilly will lead target selection and collaborate with Insilico on discovery efforts that use Insilico’s Pharma.AI platform to identify oral drug candidates across multiple therapeutic areas.
This deal builds on prior arrangements, including a 2023 AI software license and a November 2025 partnership involving $100 million. The expanded pact gives Lilly exclusive rights to certain preclinical oral assets, marking a shift from software licensing to co-development and commercialization.
Insilico, a Hong Kong–based clinical-stage AI biotechnology company founded in 2014 and listed on the Hong Kong Exchange as 3696, has developed computational discovery tools and partnerships with larger pharmaceutical firms.
Earlier reports cited a milestone total of roughly $2 billion, but later confirmations set the figure at about $2.75 billion, reflecting evolving expectations for AI-driven drug discovery deals. The structure—upfront payment, milestone pool, and royalties—shifts more value to the AI developer while preserving commercialization control for Lilly.
Andrew Adams, Group Vice President of Molecule Discovery at Lilly, said, "Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas."
